Effects of antidiabetic drugs on bone metabolism

The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding of the impact of antidiabetic drugs on bone metabolism is crucial. A descri...

Full description

Saved in:
Bibliographic Details
Published in:Advances in laboratory medicine 2024-03, Vol.5 (1), p.85-89
Main Authors: Padilla Apuntate, Nuria, Puerto Cabeza, Carmen G., Gallego Royo, Alba, Goñi Ros, Nuria, Abadía Molina, Claudia, Acha Pérez, Javier, Calmarza, Pilar
Format: Article
Language:English
Subjects:
antidiabetic drugs
bone remodeling markers
diabetes mellitus type 2
pioglitazone
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding of the impact of antidiabetic drugs on bone metabolism is crucial. A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (β-CTx) were determined. β-CTx concentrations were higher in the patients treated with pioglitazone, as compared to patients treated with DPP4i (p=0.035), SGLT2i (p=0.020) or GLP1ra (p
ISSN:2628-491X
2628-491X
DOI:10.1515/almed-2024-0038